These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25535218)

  • 1. Prospective evaluation of the cost of diagnosis and treatment of invasive fungal disease in a cohort of adult haematology patients in the UK.
    Ceesay MM; Sadique Z; Harris R; Ehrlich A; Adams EJ; Pagliuca A
    J Antimicrob Chemother; 2015 Apr; 70(4):1175-81. PubMed ID: 25535218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals.
    Rieger CT; Cornely OA; Hoppe-Tichy T; Kiehl M; Knoth H; Thalheimer M; Schuler U; Ullmann AJ; Ehlken B; Ostermann H
    Mycoses; 2012 Nov; 55(6):514-20. PubMed ID: 22471310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
    Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
    J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based analysis of attributable hospitalisation costs of invasive fungal diseases in haematological malignancy patients using data linkage of state-wide registry and costing databases: 2009-2015.
    Valentine JC; Morrissey CO; Tacey MA; Liew D; Patil S; Ananda-Rajah M
    Mycoses; 2020 Feb; 63(2):162-171. PubMed ID: 31715052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggers for driving treatment of at-risk patients with invasive fungal disease.
    Drgona L; Colita A; Klimko N; Rahav G; Ozcan MA; Donnelly JP
    J Antimicrob Chemother; 2013 Nov; 68 Suppl 3():iii17-iii24. PubMed ID: 24155142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRE) Study.
    Harrison D; Muskett H; Harvey S; Grieve R; Shahin J; Patel K; Sadique Z; Allen E; Dybowski R; Jit M; Edgeworth J; Kibbler C; Barnes R; Soni N; Rowan K
    Health Technol Assess; 2013 Feb; 17(3):1-156. PubMed ID: 23369845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
    Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
    PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
    Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.
    Doan TN; Kirkpatrick CM; Walker P; Slavin MA; Ananda-Rajah MR; Morrissey CO; Urbancic KF; Grigg A; Spencer A; Szer J; Seymour JF; Kong DC
    J Antimicrob Chemother; 2016 Feb; 71(2):497-505. PubMed ID: 26518050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
    Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
    Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients.
    Heng SC; Slavin MA; Chen SC; Heath CH; Nguyen Q; Billah B; Nation RL; Kong DC
    J Antimicrob Chemother; 2012 Sep; 67(9):2274-82. PubMed ID: 22643193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.
    Ananda-Rajah MR; Cheng A; Morrissey CO; Spelman T; Dooley M; Neville AM; Slavin M
    Antimicrob Agents Chemother; 2011 May; 55(5):1953-60. PubMed ID: 21357302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile].
    Barraza M; Barnafi N; Ortiz G; Torres JP; Coria P; Catalán P; Palma J; Morales J
    Rev Chilena Infectol; 2018 Aug; 35(4):351-357. PubMed ID: 30534920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the multidisciplinary team in antifungal stewardship.
    Agrawal S; Barnes R; Brüggemann RJ; Rautemaa-Richardson R; Warris A
    J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii37-ii42. PubMed ID: 27880668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease.
    Affolter K; Tamm M; Jahn K; Halter J; Passweg J; Hirsch HH; Stolz D
    Am J Respir Crit Care Med; 2014 Aug; 190(3):309-17. PubMed ID: 25007380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.
    Sung AH; Marcella SW; Xie Y
    J Med Econ; 2015 May; 18(5):341-8. PubMed ID: 25524741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China.
    Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
    Clin Ther; 2017 Sep; 39(9):1758-1768. PubMed ID: 28756883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.